Annual CAPEX
$5.65 B
+$3.56 B+170.02%
31 December 2023
Summary:
Novo Nordisk A/S annual capital expenditures is currently $5.65 billion, with the most recent change of +$3.56 billion (+170.02%) on 31 December 2023. During the last 3 years, it has risen by +$2.26 billion (+66.91%). NVO annual CAPEX is now at all-time high.NVO CAPEX Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CAPEX
$1.91 B
+$11.09 M+0.58%
30 September 2024
Summary:
Novo Nordisk A/S quarterly capital expenditures is currently $1.91 billion, with the most recent change of +$11.09 million (+0.58%) on 30 September 2024. Over the past year, it has increased by +$360.04 million (+23.23%). NVO quarterly CAPEX is now -19.31% below its all-time high of $2.37 billion, reached on 31 December 2023.NVO Quarterly CAPEX Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CAPEX
$7.49 B
+$360.04 M+5.05%
30 September 2024
Summary:
Novo Nordisk A/S TTM capital expenditures is currently $7.49 billion, with the most recent change of +$360.04 million (+5.05%) on 30 September 2024. Over the past year, it has increased by +$3.28 billion (+77.89%). NVO TTM CAPEX is now at all-time high.NVO TTM CAPEX Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NVO CAPEX Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +170.0% | +23.2% | +77.9% |
| 3 y3 years | +66.9% | +647.0% | +172.7% |
| 5 y5 years | +187.3% | +436.6% | +297.8% |
NVO CAPEX High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +380.6% | -19.3% | +647.0% | at high | +537.3% |
| 5 y | 5 years | at high | +380.6% | -19.3% | +845.8% | at high | +537.3% |
| alltime | all time | at high | +2876.0% | -19.3% | +3355.4% | at high | >+9999.0% |
Novo Nordisk A/S CAPEX History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $1.91 B(+0.6%) | $7.49 B(+5.1%) |
| June 2024 | - | $1.90 B(+44.7%) | $7.13 B(+13.7%) |
| Mar 2024 | - | $1.31 B(-44.6%) | $6.27 B(+11.0%) |
| Dec 2023 | $5.65 B(+170.0%) | $2.37 B(+52.7%) | $5.65 B(+34.1%) |
| Sept 2023 | - | $1.55 B(+49.4%) | $4.21 B(+31.6%) |
| June 2023 | - | $1.04 B(+49.8%) | $3.20 B(+27.1%) |
| Mar 2023 | - | $692.37 M(-25.5%) | $2.52 B(+20.3%) |
| Dec 2022 | $2.09 B(+78.0%) | $929.81 M(+72.8%) | $2.09 B(+36.4%) |
| Sept 2022 | - | $538.12 M(+51.6%) | $1.53 B(+22.6%) |
| June 2022 | - | $354.95 M(+32.2%) | $1.25 B(+4.1%) |
| Mar 2022 | - | $268.52 M(-27.7%) | $1.20 B(+2.2%) |
| Dec 2021 | $1.18 B(-65.3%) | $371.15 M(+45.1%) | $1.18 B(-57.2%) |
| Sept 2021 | - | $255.70 M(-16.2%) | $2.75 B(-21.0%) |
| June 2021 | - | $305.26 M(+25.6%) | $3.48 B(+3.1%) |
| Mar 2021 | - | $243.00 M(-87.5%) | $3.37 B(-0.3%) |
| Dec 2020 | $3.38 B(+100.9%) | $1.94 B(+97.1%) | $3.38 B(+78.6%) |
| Sept 2020 | - | $985.16 M(+387.8%) | $1.89 B(+49.7%) |
| June 2020 | - | $201.96 M(-20.6%) | $1.27 B(-14.3%) |
| Mar 2020 | - | $254.37 M(-43.9%) | $1.48 B(-12.3%) |
| Dec 2019 | $1.68 B(-14.3%) | $453.09 M(+27.3%) | $1.68 B(-10.5%) |
| Sept 2019 | - | $355.93 M(-13.8%) | $1.88 B(-3.8%) |
| June 2019 | - | $412.79 M(-10.7%) | $1.96 B(+0.9%) |
| Mar 2019 | - | $462.21 M(-29.0%) | $1.94 B(-1.3%) |
| Dec 2018 | $1.97 B(+49.3%) | $651.39 M(+51.3%) | $1.97 B(+10.8%) |
| Sept 2018 | - | $430.43 M(+8.7%) | $1.77 B(+4.7%) |
| June 2018 | - | $396.01 M(-18.8%) | $1.70 B(+8.8%) |
| Mar 2018 | - | $487.99 M(+6.0%) | $1.56 B(+18.4%) |
| Dec 2017 | $1.32 B(+7.1%) | $460.28 M(+31.0%) | $1.32 B(+4.5%) |
| Sept 2017 | - | $351.28 M(+35.3%) | $1.26 B(-2.6%) |
| June 2017 | - | $259.54 M(+5.8%) | $1.29 B(-0.9%) |
| Mar 2017 | - | $245.26 M(-39.3%) | $1.31 B(+6.2%) |
| Dec 2016 | $1.23 B(+28.9%) | $403.78 M(+4.8%) | $1.23 B(-5.3%) |
| Sept 2016 | - | $385.21 M(+42.1%) | $1.30 B(+17.3%) |
| June 2016 | - | $271.11 M(+60.7%) | $1.11 B(+10.5%) |
| Mar 2016 | - | $168.70 M(-64.3%) | $1.00 B(+5.0%) |
| Dec 2015 | $953.04 M(+23.9%) | $472.17 M(+142.9%) | $953.04 M(+25.9%) |
| Sept 2015 | - | $194.36 M(+17.2%) | $756.87 M(+1.6%) |
| June 2015 | - | $165.80 M(+37.3%) | $744.86 M(+0.3%) |
| Mar 2015 | - | $120.71 M(-56.3%) | $742.58 M(-3.4%) |
| Dec 2014 | $768.91 M(+18.6%) | $276.00 M(+51.4%) | $768.91 M(+19.1%) |
| Sept 2014 | - | $182.35 M(+11.5%) | $645.58 M(-0.0%) |
| June 2014 | - | $163.52 M(+11.2%) | $645.84 M(+1.4%) |
| Mar 2014 | - | $147.04 M(-3.7%) | $636.79 M(-1.8%) |
| Dec 2013 | $648.32 M(+3.6%) | $152.67 M(-16.4%) | $648.32 M(-8.0%) |
| Sept 2013 | - | $182.61 M(+18.2%) | $704.79 M(+2.2%) |
| June 2013 | - | $154.47 M(-2.6%) | $689.54 M(+0.6%) |
| Mar 2013 | - | $158.56 M(-24.2%) | $685.14 M(+9.5%) |
| Dec 2012 | $625.49 M | $209.15 M(+25.0%) | $625.49 M(-4.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2012 | - | $167.35 M(+11.5%) | $651.84 M(+6.5%) |
| June 2012 | - | $150.08 M(+51.7%) | $612.06 M(+0.4%) |
| Mar 2012 | - | $98.92 M(-58.0%) | $609.80 M(-2.0%) |
| Dec 2011 | $622.43 M(-10.1%) | $235.50 M(+84.6%) | $622.43 M(-3.5%) |
| Sept 2011 | - | $127.56 M(-13.7%) | $645.04 M(-4.8%) |
| June 2011 | - | $147.82 M(+32.5%) | $677.53 M(+4.1%) |
| Mar 2011 | - | $111.55 M(-56.8%) | $650.68 M(-6.0%) |
| Dec 2010 | $692.35 M(+20.7%) | $258.11 M(+61.3%) | $692.35 M(+7.2%) |
| Sept 2010 | - | $160.05 M(+32.3%) | $645.96 M(-0.4%) |
| June 2010 | - | $120.98 M(-21.0%) | $648.71 M(+2.7%) |
| Mar 2010 | - | $153.22 M(-27.6%) | $631.85 M(+10.2%) |
| Dec 2009 | $573.61 M(+42.5%) | $211.71 M(+30.0%) | $573.61 M(+11.2%) |
| Sept 2009 | - | $162.81 M(+56.4%) | $515.91 M(+17.3%) |
| June 2009 | - | $104.11 M(+9.6%) | $439.79 M(-0.6%) |
| Mar 2009 | - | $94.98 M(-38.3%) | $442.23 M(+9.9%) |
| Dec 2008 | $402.53 M(-9.9%) | $154.01 M(+77.6%) | $402.53 M(+4.4%) |
| Sept 2008 | - | $86.69 M(-18.6%) | $385.57 M(-7.4%) |
| June 2008 | - | $106.55 M(+92.8%) | $416.44 M(-1.4%) |
| Mar 2008 | - | $55.28 M(-59.7%) | $422.51 M(-5.4%) |
| Dec 2007 | $446.71 M(-20.0%) | $137.04 M(+16.6%) | $446.71 M(-8.2%) |
| Sept 2007 | - | $117.57 M(+4.4%) | $486.54 M(-5.6%) |
| June 2007 | - | $112.62 M(+41.7%) | $515.50 M(-4.9%) |
| Mar 2007 | - | $79.48 M(-55.1%) | $541.85 M(-3.0%) |
| Dec 2006 | $558.63 M(-14.2%) | $176.88 M(+20.7%) | $558.63 M(-9.4%) |
| Sept 2006 | - | $146.52 M(+5.4%) | $616.40 M(-3.7%) |
| June 2006 | - | $138.97 M(+44.4%) | $640.35 M(+3.4%) |
| Mar 2006 | - | $96.26 M(-59.0%) | $619.32 M(-4.8%) |
| Dec 2005 | $650.71 M(+23.1%) | $234.66 M(+37.7%) | $650.71 M(+3.0%) |
| Sept 2005 | - | $170.47 M(+44.5%) | $631.71 M(+4.2%) |
| June 2005 | - | $117.94 M(-7.6%) | $606.49 M(+2.5%) |
| Mar 2005 | - | $127.65 M(-40.8%) | $591.47 M(+11.9%) |
| Dec 2004 | $528.68 M(+38.2%) | $215.65 M(+48.5%) | $528.68 M(+68.9%) |
| Sept 2004 | - | $145.25 M(+41.1%) | $313.03 M(+86.6%) |
| June 2004 | - | $102.92 M(+58.7%) | $167.78 M(+158.7%) |
| Mar 2004 | - | $64.86 M | $64.86 M |
| Dec 2003 | $382.55 M(-23.9%) | - | - |
| Dec 2002 | $502.57 M(+6.3%) | - | - |
| Dec 2001 | $472.89 M(+61.2%) | - | - |
| Dec 2000 | $293.29 M(+50.3%) | - | - |
| Dec 1999 | $195.09 M(-26.0%) | - | - |
| Dec 1998 | $263.69 M(-33.4%) | - | - |
| Dec 1997 | $395.85 M(+12.1%) | - | - |
| Dec 1996 | $353.26 M(+23.6%) | - | - |
| Dec 1995 | $285.79 M(+4.4%) | - | - |
| Dec 1994 | $273.81 M(-26.1%) | - | - |
| Dec 1993 | $370.54 M(+14.3%) | - | - |
| Dec 1992 | $324.10 M(+53.1%) | - | - |
| Dec 1991 | $211.63 M(+11.5%) | - | - |
| Dec 1990 | $189.75 M | - | - |
FAQ
- What is Novo Nordisk A/S annual capital expenditures?
- What is the all time high annual CAPEX for Novo Nordisk A/S?
- What is Novo Nordisk A/S annual CAPEX year-on-year change?
- What is Novo Nordisk A/S quarterly capital expenditures?
- What is the all time high quarterly CAPEX for Novo Nordisk A/S?
- What is Novo Nordisk A/S quarterly CAPEX year-on-year change?
- What is Novo Nordisk A/S TTM capital expenditures?
- What is the all time high TTM CAPEX for Novo Nordisk A/S?
- What is Novo Nordisk A/S TTM CAPEX year-on-year change?
What is Novo Nordisk A/S annual capital expenditures?
The current annual CAPEX of NVO is $5.65 B
What is the all time high annual CAPEX for Novo Nordisk A/S?
Novo Nordisk A/S all-time high annual capital expenditures is $5.65 B
What is Novo Nordisk A/S annual CAPEX year-on-year change?
Over the past year, NVO annual capital expenditures has changed by +$3.56 B (+170.02%)
What is Novo Nordisk A/S quarterly capital expenditures?
The current quarterly CAPEX of NVO is $1.91 B
What is the all time high quarterly CAPEX for Novo Nordisk A/S?
Novo Nordisk A/S all-time high quarterly capital expenditures is $2.37 B
What is Novo Nordisk A/S quarterly CAPEX year-on-year change?
Over the past year, NVO quarterly capital expenditures has changed by +$360.04 M (+23.23%)
What is Novo Nordisk A/S TTM capital expenditures?
The current TTM CAPEX of NVO is $7.49 B
What is the all time high TTM CAPEX for Novo Nordisk A/S?
Novo Nordisk A/S all-time high TTM capital expenditures is $7.49 B
What is Novo Nordisk A/S TTM CAPEX year-on-year change?
Over the past year, NVO TTM capital expenditures has changed by +$3.28 B (+77.89%)